Literature DB >> 1603342

Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy.

M B Bromberg1, E L Feldman, J W Albers.   

Abstract

We reviewed our data from patients with the clinical diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Seventy patients had no demonstrable underlying disease to account for their polyneuropathy and were classified as idiopathic CIDP (CIDP-I). We detected a monoclonal gammopathy of uncertain significance (MGUS) in 30 patients who were classified as CIDP-MGUS; 17 had an IgG gammopathy, 12 an IgM gammopathy, and one an IgA gammopathy. Compared with CIDP-I patients, CIDP-MGUS patients were older and slightly more likely to be males. When compared with patients with an MGUS but without polyneuropathy reported in the literature, CIDP-MGUS patients had similar distributions of age, sex, and immunoglobulin class. There were no significant differences in motor and sensory nerve conduction measures between CIDP-I and CIDP-MGUS patients, nor between CIDP-MGUS patients with IgM and those with IgG or IgA gammopathy. Strict electrodiagnostic criteria for primary demyelination were fulfilled by 54% of CIDP-I patients and 40% of CIDP-MGUS patients, but these were not significantly different. Our study suggests that (1) the demographic features and immunoglobulin class distribution of CIDP-MGUS patients largely reflect those of patients with an MGUS, but without polyneuropathy, (2) CIDP-MGUS patients as a group cannot be distinguished from CIDP-I patients on the basis of nerve conduction studies, and (3) IgM CIDP-MGUS patients cannot be distinguished from those with other immunoglobulin classes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1603342     DOI: 10.1212/wnl.42.6.1157

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.

Authors:  T Maisonobe; B Chassande; M Vérin; M Jouni; J M Léger; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

Review 2.  Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Association With Concomitant Diseases: Identification and Management.

Authors:  Yan Chen; Xiangqi Tang
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 3.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 4.  Systematic reviews of treatment for inflammatory demyelinating neuropathy.

Authors:  R A C Hughes
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

Review 5.  Treatment for IgG and IgA paraproteinaemic neuropathy.

Authors:  Abraham C J Stork; Michael P T Lunn; Eduardo Nobile-Orazio; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2015-03-24

6.  Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?

Authors:  Normann Steiner; Angelika Schwärzler; Georg Göbel; Wolfgang Löscher; Julia Wanschitz; Eberhard Gunsilius
Journal:  Oncotarget       Date:  2017-01-17

7.  Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients.

Authors:  Nuha M Alkhawajah; Samantha K Dunnigan; Vera Bril
Journal:  J Neurol       Date:  2014-05-07       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.